Novartis announces expiration of HSR waiting period of Regulus Therapeutics tender offer

Novartis announces expiration of HSR waiting period of Regulus Therapeutics tender offer
arcticnovartis

Basel, June 23, 2025 – Novartis today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection with Novartis’ previously announced tender offer to acquire all of the outstanding shares of common stock, par value $0.001 per share (the “Shares”), of Regulus Therapeutics Inc.